Results 111 to 115 of about 400 (115)

Faculty Opinions recommendation of First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2017
openaire   +1 more source

Faculty Opinions recommendation of A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2017
openaire   +1 more source

Dose Interruptions with Morphine vs Oliceridine (TRV130), a Novel μ Receptor G Protein Pathway Selective (μ-GPS) Modulator: Analysis from a Placebo- and Morphine-Controlled Phase 2b Study in Patients Following Abdominoplasty

Journal of the American College of Surgeons, 2016
Anthony J. Senagore, David Soergel, David Burt, Franck Skobieranda, Neil Singla   +4 more
openaire   +1 more source

Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain

Journal of Medicinal Chemistry, 2013
Conrad L Cowan, Scott M Dewire, Jonathan D Violin   +2 more
exaly  

Faculty Opinions recommendation of Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2017
openaire   +1 more source